<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7102518/results/search/disease/results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="human health globally. In addition to further improving vaccine prophylaxis," exact="disease" post="management through antiviral therapeutics constitutes an important component of"/>
  <result pre="of the current intervention strategy to prevent advance to complicated" exact="disease" post="and reduce case-fatality rates. Standard-of-care is treatment with neuraminidase"/>
  <result pre="case-fatality rates. Standard-of-care is treatment with neuraminidase inhibitors that prevent" exact="viral" post="dissemination. In 2018, the first mechanistically new influenza drug"/>
  <result pre="for human use. Targeting the PA endonuclease subunit of the" exact="viral" post="polymerase complex, this class suppresses viral replication. However, the"/>
  <result pre="endonuclease subunit of the viral polymerase complex, this class suppresses" exact="viral" post="replication. However, the genetic barrier against viral resistance to"/>
  <result pre="this class suppresses viral replication. However, the genetic barrier against" exact="viral" post="resistance to both drug classes is low, pre-existing resistance"/>
  <result pre="Abbreviations RBC, red blood cells PK, pharmacokinetics CDC, centers for" exact="disease" post="control and prevention IAV, influenza A virus IBV, influenza"/>
  <result pre="the population during every season. In most healthy individuals, these" exact="infections" post="predominantly result in relatively mild, self-limiting disease that remains"/>
  <result pre="healthy individuals, these infections predominantly result in relatively mild, self-limiting" exact="disease" post="that remains restricted to the upper respiratory tract and"/>
  <result pre="in relatively mild, self-limiting disease that remains restricted to the" exact="upper" post="respiratory tract and does not require therapeutic intervention. Reflecting"/>
  <result pre="relatively mild, self-limiting disease that remains restricted to the upper" exact="respiratory" post="tract and does not require therapeutic intervention. Reflecting the"/>
  <result pre="and does not require therapeutic intervention. Reflecting the overall high" exact="disease" post="prevalence, however, the World Health Organization estimates that 3–5"/>
  <result pre="prevalence, however, the World Health Organization estimates that 3–5 million" exact="infections" post="lead to severe disease that advances to the lower"/>
  <result pre="Health Organization estimates that 3–5 million infections lead to severe" exact="disease" post="that advances to the lower respiratory tract and viral"/>
  <result pre="million infections lead to severe disease that advances to the" exact="lower" post="respiratory tract and viral pneumonia, resulting in up to"/>
  <result pre="infections lead to severe disease that advances to the lower" exact="respiratory" post="tract and viral pneumonia, resulting in up to 650,000"/>
  <result pre="severe disease that advances to the lower respiratory tract and" exact="viral pneumonia," post="resulting in up to 650,000 deaths annually.1 High-risk groups"/>
  <result pre="up to 650,000 deaths annually.1 High-risk groups for severe influenza" exact="infection" post="include older adults, the immunocompromized, pregnant women, people with"/>
  <result pre="include older adults, the immunocompromized, pregnant women, people with underlying" exact="pulmonary" post="conditions, and, to a lesser degree, the very young."/>
  <result pre="the highest mortality rate since the 2009 H1N1 pandemic.2 Although" exact="disease" post="burden was particularly high in that season, vaccination efficacy"/>
  <result pre="is particularly low in older adults, leaving one of the" exact="primary" post="at-risk groups poorly protected (reviewed in5). Due to these"/>
  <result pre="to these limitations to vaccine prophylaxis combined with continued high" exact="disease" post="burden caused by seasonal influenza viruses, the threat of"/>
  <result pre="seasonal influenza viruses, the threat of spill-over of highly pathogenic" exact="avian influenza" post="viruses into the human population and a low barrier"/>
  <result pre="viruses into the human population and a low barrier to" exact="viral" post="escape of standard-of-care therapeutics (discussed in detail below), effective"/>
  <result pre="below), effective novel antiviral therapeutics are urgently needed for improved" exact="disease" post="management especially in high risk patients and for heightened"/>
  <result pre="THERAPEUTIC WINDOW FOR TARGETING OF INFLUENZA VIRUS REPLICATION Whereas influenza" exact="virus infection" post="causes direct cell damage in the airway epithelium, severe"/>
  <result pre="WINDOW FOR TARGETING OF INFLUENZA VIRUS REPLICATION Whereas influenza virus" exact="infection" post="causes direct cell damage in the airway epithelium, severe"/>
  <result pre="damage in the airway epithelium, severe tissue damage during complicated" exact="disease" post="is largely a consequence of immunopathogenesis and peaks after"/>
  <result pre="is largely a consequence of immunopathogenesis and peaks after the" exact="acute" post="infection has been cleared. Influenza virus load in the"/>
  <result pre="largely a consequence of immunopathogenesis and peaks after the acute" exact="infection" post="has been cleared. Influenza virus load in the upper"/>
  <result pre="acute infection has been cleared. Influenza virus load in the" exact="upper" post="respiratory tract is highest approximately 2–3 days after infection,"/>
  <result pre="infection has been cleared. Influenza virus load in the upper" exact="respiratory" post="tract is highest approximately 2–3 days after infection, which"/>
  <result pre="after infection, which coincides with peak fever and most pronounced" exact="respiratory" post="clinical signs. After the third day of infection, virus"/>
  <result pre="is increasingly immune controlled and virus load drops rapidly.6 Rapid" exact="disease" post="progression and, in the case of uncomplicated disease, immune"/>
  <result pre="greatest when antiviral drugs were administered within 24 hours of" exact="disease" post="manifestation.9, 10, 11 Accordingly, public disease awareness, proactive patient"/>
  <result pre="within 24 hours of disease manifestation.9, 10, 11 Accordingly, public" exact="disease" post="awareness, proactive patient behavior, and access to rapid diagnostics"/>
  <result pre="otherwise healthy patients and concerns of promoting the development of" exact="viral" post="resistance. INFLUENZA VIRUS RESISTANCE TO ANTIVIRALS All currently approved"/>
  <result pre="concerns of promoting the development of viral resistance. INFLUENZA VIRUS" exact="RESISTANCE TO" post="ANTIVIRALS All currently approved influenza drugs interfere with viral"/>
  <result pre="RESISTANCE TO ANTIVIRALS All currently approved influenza drugs interfere with" exact="viral" post="protein function and therefore belong to the group of"/>
  <result pre="host-directed experimental antivirals, drugs of the DAA group have a" exact="lower" post="tendency for undesirable side effects. However, rapid development of"/>
  <result pre="lower tendency for undesirable side effects. However, rapid development of" exact="viral" post="resistance has emerged as the predominant liability of DAAs,"/>
  <result pre="directed against RNA viruses with error prone polymerases such as" exact="respiratory" post="syncytial virus (RSV)15,16 or the influenza viruses.17 Exemplifying the"/>
  <result pre="of influenza A virus (IAV) infections. These inhibitors target the" exact="viral" post="M2 ion channel, preventing dissociation of the viral ribonucleoprotein"/>
  <result pre="target the viral M2 ion channel, preventing dissociation of the" exact="viral" post="ribonucleoprotein (RNP) genome from the matrix protein by blocking"/>
  <result pre="CDC for more than a decade due to widespread pre-existing" exact="viral" post="resistance.21, 22, 23 In the 2019 influenza season, for"/>
  <result pre="mutations were detected in highly pathogenic avian H5N1 strains.26,27 To" exact="lower" post="the risk of triggering the emergence of resistance against"/>
  <result pre="against the development of resistance. Mechanistically unique is the host-directed" exact="viral" post="entry inhibitor DAS181, a recombinant sialidase fusion protein, which"/>
  <result pre="protein, which targets cellular sialic acid residues required for influenza" exact="virus infection." post="In contrast to this extracellular host target, the majority"/>
  <result pre="approved yet for clinical use against influenza viruses29,30 or other" exact="respiratory" post="RNA viruses of the myxo- and pneumovirus families. CLINICALLY"/>
  <result pre="for influenza management since essentially all circulating influenza viruses have" exact="acquired" post="resistance to the adamantanes. Mechanistically, NAIs competitively inhibits the"/>
  <result pre="NAIs could have enhanced the risk of progression to severe" exact="disease" post="in the 2009/2010 pandemic.38 Resistance to oseltamivir can develop"/>
  <result pre="risk of progression to severe disease in the 2009/2010 pandemic.38" exact="Resistance" post="to oseltamivir can develop rapidly in both experimental settings"/>
  <result pre="typically originates from substitutions at signature resistance sites in the" exact="viral" post="NA protein such as H274Y and I223R (predominant in"/>
  <result pre="receptor binding sites (RBCs) is highly immunogenic and thus a" exact="primary" post="target for nAbs. However, these head-directed anti-influenza nAbs typically"/>
  <result pre="Whereas no resistant viruses emerged in these clinical trials, 2" exact="viral" post="escape pathways from HA stalk-directed antibodies have been identified"/>
  <result pre="pathways from HA stalk-directed antibodies have been identified experimentally63: after" exact="viral" post="adaptation in cell culture, resistant variants either carried a"/>
  <result pre="harbored substitutions that enhanced HA fusion activity and therefore allowed" exact="viral" post="entry in the presence of antibody. These experimental resistance"/>
  <result pre="in the presence of antibody. These experimental resistance mutations affected" exact="viral" post="fitness, however, reducing viral replication in cell culture. Major"/>
  <result pre="antibody. These experimental resistance mutations affected viral fitness, however, reducing" exact="viral" post="replication in cell culture. Major concerns for the use"/>
  <result pre="as a consequence of poor distribution from blood to the" exact="upper" post="airways, and the high manufacturing costs of biologics. Since"/>
  <result pre="the large patient group of nonhospitalized adults suffering from uncomplicated" exact="disease" post="is expected when the drug is orally bioavailable and"/>
  <result pre="groups or hospitalized patients with complicated disease. Inhibitors of the" exact="viral" post="polymerase complex In the last decade, the viral RNA-dependent"/>
  <result pre="of the viral polymerase complex In the last decade, the" exact="viral" post="RNA-dependent RNA polymerase (RdRP) complex has emerged as an"/>
  <result pre="do not exist as naked RNA but are encapsidated by" exact="viral" post="NP proteins, forming RNP complexes. Whereas replication requires the"/>
  <result pre="that are then copied into progeny negative polarity segments (vRNPs)," exact="viral" post="message is directly synthesized from vRNPs. Since the influenza"/>
  <result pre="the PA subunit is instrumental for the generation of bioactive" exact="viral" post="mRNAs through transfer of 5′-capped RNA primers derived from"/>
  <result pre="approved in 2 decades for the treatment of uncomplicated influenza" exact="infection" post="in patients older than 12 years of age.70 Taken"/>
  <result pre="better than, current standard-of-care.71,72 In clinical trials, participants showed significantly" exact="lower" post="viral burden 1 day after initiation of treatment compared"/>
  <result pre="than, current standard-of-care.71,72 In clinical trials, participants showed significantly lower" exact="viral" post="burden 1 day after initiation of treatment compared to"/>
  <result pre="lethal dose of a highly pathogenic avian IAV resulted in" exact="complete" post="survival of the animals and reduction of viral load"/>
  <result pre="resulted in complete survival of the animals and reduction of" exact="viral" post="load in the respiratory tract. Similarly profound efficacy was"/>
  <result pre="of the animals and reduction of viral load in the" exact="respiratory" post="tract. Similarly profound efficacy was observed in immunocompromized mice.73,"/>
  <result pre="was well tolerated in clinical trials with only mild and" exact="transient" post="adverse events that resolved without further intervention. Side effects"/>
  <result pre="baloxavir marboxil, resistant viruses emerged in up to 9.7% of" exact="adult" post="clinical trial participants and 23.4% of children.72,79 In several"/>
  <result pre="and ferrets, both loss of animal body weight and lung" exact="viral" post="loads were identical after infection with resistant or sensitive"/>
  <result pre="animal body weight and lung viral loads were identical after" exact="infection" post="with resistant or sensitive viruses, and substitutions at PA"/>
  <result pre="resistant or sensitive viruses, and substitutions at PA I38 remained" exact="stable" post="over 4 passages through mice.85,86 A small percentage of"/>
  <result pre="is low and that escape comes with little penalty to" exact="viral" post="fitness, pathogenesis, or transmission success. Accordingly, there is considerable"/>
  <result pre="to a ribonucleoside analog through phosphoribosylation, thus competitively targeting the" exact="viral" post="RdRP complex. Anabolism efficiency can vary between cells of"/>
  <result pre="origin, but has been shown to be low in disease-relevant" exact="primary" post="human airway epithelium cells.90 The drug has broad-spectrum antiviral"/>
  <result pre="Mechanistically, T-705 is incorporated into newly synthesized RNA by the" exact="viral" post="polymerase in place of purines but not pyrimidines,95 resulting"/>
  <result pre="and G-to-A transition mutations as demonstrated for influenza viruses and" exact="hepatitis" post="C virus both in vitro and in vivo.96, 97,"/>
  <result pre="resulting from the accumulation of random low-frequency mutations in the" exact="viral" post="genome (Fig 2 ). The genetic barrier of T-705"/>
  <result pre="the PB1 (K229R) and PA (P659L) polymerase subunits that reduce" exact="viral" post="sensitivity to the compound by approximately 30-fold in cell"/>
  <result pre="mutagenesis induced by ribonucleoside analogs EIDD-2801 and T-705. In the" exact="absence of" post="drug, random mutation frequency in the virus population is"/>
  <result pre="the random mutation frequency beyond a tolerable threshold, resulting in" exact="collapse" post="of the virus population (red); MOA, mechanism of action."/>
  <result pre="as children or pregnant women.103 Activity assessment against other potential" exact="viral" post="targets in animal models furthermore revealed that in vivo"/>
  <result pre="poor and dependent on extremely high dose concentrations.104,105 These results" exact="lower" post="the clinical value of T-705 and undermine its use"/>
  <result pre="efficiently anabolized to the bioactive tri-phosphate form in ex vivo" exact="primary" post="human airway epithelium cultures and in animal tissues, followed"/>
  <result pre="and in animal tissues, followed by incorporation as cytidine into" exact="viral" post="RNA by influenza virus polymerases.90,106 Tautomeric interconversions then cause"/>
  <result pre="resulting in high-frequency random C-to-U and G-to-A transition mutations in" exact="viral" post="RNA replication or transcription products and thus inhibition through"/>
  <result pre="IAV strains in the ferret model, causing significant reduction of" exact="viral" post="load in both the upper and lower respiratory tract"/>
  <result pre="model, causing significant reduction of viral load in both the" exact="upper" post="and lower respiratory tract and alleviation of clinical signs."/>
  <result pre="significant reduction of viral load in both the upper and" exact="lower" post="respiratory tract and alleviation of clinical signs. The compound"/>
  <result pre="reduction of viral load in both the upper and lower" exact="respiratory" post="tract and alleviation of clinical signs. The compound showed"/>
  <result pre="&amp;gt;1700. EIDD-2801/NHC appears to establish an unusually high barrier against" exact="viral" post="resistance, since several studies have unsuccessfully tried to induce"/>
  <result pre="viral resistance, since several studies have unsuccessfully tried to induce" exact="viral" post="escape through dose-escalation and sublethal fixed-dose adaptation strategies. Next-generation"/>
  <result pre="for instance, by the compromised safety profile of T-705.99,102 A" exact="primary" post="source for adverse effects is incorporation of the ribonucleoside"/>
  <result pre="of NHC-characteristic transition events was noted after prolonged exposure of" exact="primary" post="human airway epithelium cells to the drug. However, the"/>
  <result pre="polymerase PB2 subunit. The drug outperformed current standard-of-care in animal" exact="infection" post="models of H3N2 and H1N1 viruses, although potency was"/>
  <result pre="compound was well-tolerated in a phase 2 clinical trial, reduced" exact="viral" post="load, and resulted in slightly faster resolve of clinical"/>
  <result pre="6.4% of trial participants, indicating that the genetic barrier to" exact="viral" post="escape from the drug is low. Compared to standard-of-care,"/>
  <result pre="genetic barriers of both neuraminidase and PA endonuclease inhibitors against" exact="viral" post="escape create an urgent need for next-generation therapeutics. Of"/>
  <result pre="U S A992002162491625412444251 2UminoY.KohamaT.SatoT.A.SugiuraA.KlenkH.D.RottR.Monoclonal antibodies to three structural proteins of" exact="Newcastle disease" post="virus: biological characterization with particular reference to the conformational"/>
  <result pre="S A992002162491625412444251 2UminoY.KohamaT.SatoT.A.SugiuraA.KlenkH.D.RottR.Monoclonal antibodies to three structural proteins of Newcastle" exact="disease" post="virus: biological characterization with particular reference to the conformational"/>
  <result pre="5DuganH.L.HenryC.WilsonP.C.Aging and influenza vaccine-induced immunityCell Immunol2019103998 6BaccamP.BeaucheminC.MackenC.A.HaydenF.G.PerelsonA.S.Kinetics of influenza A" exact="virus infection" post="in humansJ Virol8020067590759916840338 7DobsonJ.WhitleyR.J.PocockS.MontoA.S.Oseltamivir treatment for influenza in adults:"/>
  <result pre="and influenza vaccine-induced immunityCell Immunol2019103998 6BaccamP.BeaucheminC.MackenC.A.HaydenF.G.PerelsonA.S.Kinetics of influenza A virus" exact="infection" post="in humansJ Virol8020067590759916840338 7DobsonJ.WhitleyR.J.PocockS.MontoA.S.Oseltamivir treatment for influenza in adults:"/>
  <result pre="and safety of the oral neuraminidase inhibitor oseltamivir in treating" exact="acute" post="influenza: a randomized controlled trial. US Oral Neuraminidase Study"/>
  <result pre="Study GroupJAMA.28320001016102410697061 11NicholsonK.G.AokiF.Y.OsterhausA.D.Efficacy and safety of oseltamivir in treatment of" exact="acute" post="influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment"/>
  <result pre="Treatment Investigator GroupLancet.35520001845185010866439 12VemulaS.V.ZhaoJ.LiuJ.WangX.BiswasS.HewlettI.Current approaches for diagnosis of influenza virus" exact="infections" post="in humansViruses820169627077877 13JacksonR.J.CooperK.L.TappendenP.Oseltamivir, zanamivir and amantadine in the prevention"/>
  <result pre="the prevention of influenza: a systematic reviewJ Infect622011142520950645 14Centers for" exact="Disease" post="Control and Prevention. Influenza antiviral medications: summary for clincians;"/>
  <result pre="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#Treatment. (Accessed February 27, 2020). 15DeVincenzoJ.P.WhitleyR.J.MackmanR.L.Oral GS-5806 activity in a" exact="respiratory" post="syncytial virus challenge studyN Engl J Med371201471172225140957 16ChemalyR.F.DadwalS.S.BergeronA.A phase"/>
  <result pre="randomized, double-blind, placebo-controlled trial of presatovir for the treatment of" exact="respiratory" post="syncytial virus upper respiratory tract infection in hematopoietic-cell transplant"/>
  <result pre="trial of presatovir for the treatment of respiratory syncytial virus" exact="upper respiratory tract infection" post="in hematopoietic-cell transplant recipientsClin Infect Dis2019[epub ahead of print]"/>
  <result pre="of presatovir for the treatment of respiratory syncytial virus upper" exact="respiratory" post="tract infection in hematopoietic-cell transplant recipientsClin Infect Dis2019[epub ahead"/>
  <result pre="for the treatment of respiratory syncytial virus upper respiratory tract" exact="infection" post="in hematopoietic-cell transplant recipientsClin Infect Dis2019[epub ahead of print]"/>
  <result pre="cons and future perspectivesExpert Opin Pharmaco20201917111718 36EbellM.H.Oseltamivir and zanamivir have" exact="limited" post="effect on symptoms and do not reduce hospitalisation or"/>
  <result pre="47EspositoS.MolteniC.G.ColomboC.Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with" exact="cystic fibrosis" post="and Pseudomonas aeruginosa infectionJ Clin Virol482010626520335065 48van der VriesE.SchuttenM.FraaijP.BoucherC.OsterhausA.Influenza"/>
  <result pre="infantsJ Perinatol36201699099627490190 50MulanguS.DoddL.E.DaveyR.T.Jr.Tshiani MbayaO.ProschanM.MukadiD.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsN Engl J Med38120192293230331774950 51LaursenN.S.WilsonI.A.Broadly neutralizing antibodies against influenza"/>
  <result pre="Pathog82012e1003067 54BaranovichT.JonesJ.C.RussierM.The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced" exact="acute" post="respiratory distress syndromeAntimicrob Agents Chemother6020162118213126787699 55CortiD.VossJ.GamblinS.J.A neutralizing antibody selected"/>
  <result pre="54BaranovichT.JonesJ.C.RussierM.The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute" exact="respiratory" post="distress syndromeAntimicrob Agents Chemother6020162118213126787699 55CortiD.VossJ.GamblinS.J.A neutralizing antibody selected from"/>
  <result pre="novel approaches in influenza managementVaccines (Basel)7201953 65LaursenN.S.FriesenR.H.E.ZhuX.Universal protection against influenza" exact="infection" post="by a multidomain antibody to influenza hemagglutininScience362201859860230385580 66OrtinJ.Martin-BenitoJ.The RNA"/>
  <result pre="endonuclease inhibitor baloxavir marboxilSci Rep82018963329941893 83ImaiM.YamashitaM.Sakai-TagawaY.Influenza A variants with reduced" exact="susceptibility to" post="baloxavir isolated from Japanese patients are fit and transmit"/>
  <result pre="baloxavir isolated from Japanese patients are fit and transmit through" exact="respiratory" post="dropletsNat Microbiol52019273331768027 84TakashitaE.KawakamiC.MoritaH.Detection of influenza A(H3N2) viruses exhibiting reduced"/>
  <result pre="respiratory dropletsNat Microbiol52019273331768027 84TakashitaE.KawakamiC.MoritaH.Detection of influenza A(H3N2) viruses exhibiting reduced" exact="susceptibility to" post="the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December"/>
  <result pre="Surveill2420193026 85ChesnokovA.PatelM.C.MishinV.P.Replicative fitness of seasonal influenza A viruses with decreased" exact="susceptibility to" post="baloxavirJ Infect Dis221202036737131541547 86CheckmahomedL.M'HamdiZ.CarbonneauJ.Impact of the baloxavir-resistant polymerase acid"/>
  <result pre="from the Asia-Pacific, 2012-2018Antiviral Res1642019919630771405 89TakashitaE.KawakamiC.OgawaR.Influenza A(H3N2) virus exhibiting reduced" exact="susceptibility to" post="baloxavir due to a polymerase acidic subunit I38T substitution"/>
  <result pre="2019Eurosurveillance242019912 90YoonJ.J.TootsM.LeeS.Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and" exact="respiratory" post="syncytial virusesAntimicrob Agents Chemother622018e00766-1829891600 91Rocha-PereiraJ.JochmansD.DallmeierK.LeyssenP.NascimentoM.S.J.NeytsJ.Favipiravir (T-705) inhibits in vitro"/>
  <result pre="Bioph Res Co4242012777780 92JulanderJ.G.SmeeD.F.MorreyJ.D.FurutaY.Effect of T-705 treatment on western equine" exact="encephalitis" post="in a mouse modelAntiviral Res82200916917119428608 93MorreyJ.D.TaroB.S.SiddharthanV.Efficacy of orally administered"/>
  <result pre="of orally administered T-705 pyrazine analog on lethal West Nile" exact="virus infection" post="in rodentsAntiviral Res80200837737918762216 94GowenB.B.WongM.H.JungK.H.In vitro and in vivo activities"/>
  <result pre="orally administered T-705 pyrazine analog on lethal West Nile virus" exact="infection" post="in rodentsAntiviral Res80200837737918762216 94GowenB.B.WongM.H.JungK.H.In vitro and in vivo activities"/>
  <result pre="A H1N1 viruses in vitroJ Virol8720133741375123325689 97de AvilaA.I.GallegoI.SoriaM.E.Lethal mutagenesis of" exact="hepatitis" post="C virus induced by favipiravirPLoS One112016e0164691 98AriasA.ThorneL.GoodfellowI.Favipiravir elicits antiviral"/>
  <result pre="replication in vivoElife32014e0367925333492 99FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Jpn Acad Ser B Phys Biol Sci932017449463"/>
  <result pre="S A1152018116131161830352857 102NagataT.LeforA.K.HasegawaM.IshiiM.Favipiravir: a new medication for the Ebola virus" exact="disease" post="pandemicDisaster Med Public Health Prep92015798125544306 103DelangL.AbdelnabiR.NeytsJ.Favipiravir as a potential"/>
  <result pre="RNA virusesAntivir Res1532018859429524445 104YamadaK.NoguchiK.KimitsukiK.Reevaluation of the efficacy of favipiravir against" exact="rabies" post="virus using in vivo imaging analysisAntiviral Res1722019104641 105JochmansD.van NieuwkoopS.SmitsS.L.NeytsJ.FouchierR.A.van"/>
  <result pre="epitheliaSci Transl Med112019eaax586631645453 107StuyverL.J.WhitakerT.McBrayerT.R.Ribonucleoside analogue that blocks replication of bovine" exact="viral" post="diarrhea and hepatitis C viruses in cultureAntimicrob Agents Ch472003244254"/>
  <result pre="Transl Med112019eaax586631645453 107StuyverL.J.WhitakerT.McBrayerT.R.Ribonucleoside analogue that blocks replication of bovine viral" exact="diarrhea" post="and hepatitis C viruses in cultureAntimicrob Agents Ch472003244254 108UrakovaN.KuznetsovaV.CrossmanD.K.Beta-D-N-4-hydroxycytidine"/>
  <result pre="107StuyverL.J.WhitakerT.McBrayerT.R.Ribonucleoside analogue that blocks replication of bovine viral diarrhea and" exact="hepatitis" post="C viruses in cultureAntimicrob Agents Ch472003244254 108UrakovaN.KuznetsovaV.CrossmanD.K.Beta-D-N-4-hydroxycytidine is a"/>
  <result pre="compound that induces a high level of mutations in the" exact="viral" post="genomeJ Virol922018e01965-1729167335 109AgostiniM.L.PruijssersA.J.ChappellJ.D.Small molecule antiviral beta-D-N (4)-hydroxycytidine inhibits a"/>
  <result pre="ribonucleoside analog in a murine model of intranasal venezuelan equine" exact="encephalitis" post="virus infectionAntiviral Res1712019104597 112LuG.BluemlingG.R.MaoS.Simple in vitro assay to evaluate"/>
  <result pre="mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of" exact="hepatitis" post="C virusAntimicrob Agents Ch602016806817 114SultanaS.SolotchiM.RamachandranA.PatelS.S.Transcriptional fidelities of human mitochondrial"/>
  <result pre="JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus" exact="infections" post="in miceAntivir Res1362016455027771390 117ByrnR.A.JonesS.M.BennettH.B.Preclinical activity of VX-787, a first-in-class,"/>
  <result pre="as monotherapy or in combination with oseltamivir for treatment of" exact="acute" post="uncomplicated seasonal influenza A: TOPAZ trialJ Infect Dis21920191026103430428049 119ClarkM.P.LedeboerM.W.DaviesI.Discovery"/>
 </snippets>
</snippetsTree>
